This therapy-induced anti-tumor immunity may predict tumor regression, for example a tumor gene expression signature of the DNA damage immune response, including programmed cell death ligand 1 (PD-L1) and several inflammatory cytokines (CXCL9, CXCL13, CXCL10/IP-10, CXCL11, CCL5, CCL18), has been shown to predict tumor regression in EAC [23]. This evidence concerns the gene CCL18 and neoplasm.